uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QURE uniQure NV

Not Yet Opened 02-10 16:00:00 EST

24.71

-1.34

-5.14%

盘后24.78

+0.07+0.28%

19:29 EST

High26.97	Low24.61	Vol1.18M
Open25.55	D1 Closing26.05	Amplitude9.06%
Mkt Cap1.54B	Tradable Cap1.00B	Total Shares62.29M
T/O29.86M	T/O Rate2.89%	Tradable Shares40.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure NV","latestPrice":24.71,"timestamp":1770757200000,"preClose":26.05,"halted":0,"volume":1175626,"hourTrading":{"tag":"盘后","latestPrice":24.7782,"preClose":24.71,"latestTime":"19:29 EST","volume":7719,"amount":190784.1003,"timestamp":1770769760725,"change":0.0682,"changeRate":0.00276,"amplitude":0.003569},"delay":0,"changeRate":-0.05143953934740882,"floatShares":40636300,"shares":62291663,"eps":-4.344329,"marketStatus":"Not Yet Opened","change":-1.34,"latestTime":"02-10 16:00:00 EST","open":25.55,"high":26.97,"low":24.61,"amount":29863804.19622,"amplitude":0.090595,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.344329,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":26.05,"preHourTrading":{"tag":"盘前","latestPrice":25.76,"preClose":26.05,"latestTime":"09:27 EST","volume":5212,"amount":133452.77007199998,"timestamp":1770733646322,"change":-0.29,"changeRate":-0.011132,"amplitude":0.01881},"postHourTrading":{"tag":"盘后","latestPrice":24.7782,"preClose":24.71,"latestTime":"19:29 EST","volume":7719,"amount":190784.1003,"timestamp":1770769760725,"change":0.0682,"changeRate":0.00276,"amplitude":0.003569},"volumeRatio":0.505148,"impliedVol":2.1469,"impliedVolPercentile":0.984},"requestUrl":"/m/hq/s/QURE","defaultTab":"news","newsList":[{"id":"2610429086","title":"uniQure Price Target Maintained With a $70.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2610429086","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610429086?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:03","pubTimestamp":1770724980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 07:03 ET (12:03 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","QURE"],"gpt_icon":0},{"id":"2610633391","title":"How Early AMT-191 Gene Therapy Signals Will Impact uniQure (QURE) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2610633391","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610633391?lang=en_us&edition=fundamental","pubTime":"2026-02-09 14:08","pubTimestamp":1770617282,"startTime":"0","endTime":"0","summary":"uniQure N.V. recently reported updated preliminary safety and exploratory efficacy data from 11 patients in its ongoing Phase I/IIa trial of AMT-191, an investigational AAV gene therapy for Fabry disease, showing elevated α-galactosidase A activity across all three dose cohorts and a manageable safety profile.\nAn interesting early signal is that several participants have been able to discontinue enzyme replacement therapy, hinting at the potential real-world impact of a one-time gene therapy...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/how-early-amt-191-gene-therapy-signals-will-impact-uniqure-q","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/how-early-amt-191-gene-therapy-signals-will-impact-uniqure-q","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4534","BK4581","BK4219","BK4139","BK4588","AMT","QURE","ISBC","BK4084","BK4554","BK4211","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","BK4585"],"gpt_icon":0},{"id":"2609252515","title":"Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2609252515","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609252515?lang=en_us&edition=fundamental","pubTime":"2026-02-07 02:58","pubTimestamp":1770404280,"startTime":"0","endTime":"0","summary":"uniQure shares early trial data showing strong enzyme increases in Fabry patients, manageable safety results, and paused higher dosing after liver enzyme findings.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/06/Medicine-And-Health-Concept--On-A-White-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/06/Medicine-And-Health-Concept--On-A-White-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/02/50458873/early-uniqure-fabry-trial-shows-lasting-enzyme-boost-safety-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/02/50458873/early-uniqure-fabry-trial-shows-lasting-enzyme-boost-safety-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","QURE","BK4139"],"gpt_icon":0},{"id":"2609959857","title":"uniQure präsentiert neue Phase-I/IIa-Daten zur Gentherapie AMT-191 bei Fabry-Krankheit","url":"https://stock-news.laohu8.com/highlight/detail?id=2609959857","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609959857?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:05","pubTimestamp":1770379516,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via GlobeNewswire  on February 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDLbCktM9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","LU0320765992.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4139","BK4588","SG9999014013.SGD","LU0109394709.USD","QURE","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014021.USD","LU0889565916.HKD","BK4112","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2609598571","title":"uniQure Reports Sustained Enzyme Increases in Phase I/IIa Fabry Disease Gene Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2609598571","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609598571?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:05","pubTimestamp":1770379516,"startTime":"0","endTime":"0","summary":"uniQure NV has announced updated preliminary data from its Phase I/IIa clinical trial of AMT-191, an investigational AAV gene therapy for Fabry disease. The data, presented at the 22nd Annual WORLDSymposium on February 3, 2026, showed sustained and dose-dependent increases in α-Gal A enzyme activity across all dose cohorts, with supraphysiological expression maintained for over a year in the longest treated patient. Six out of eleven patients met criteria to discontinue enzyme replacement therapy, and stable plasma lyso-Gb3 levels were observed post-dosing, regardless of enzyme replacement therapy status. The safety profile remains manageable, with no serious adverse events related to AMT-191 at lower doses, though dosing in the mid- and high-dose cohorts has been paused following asymptomatic liver enzyme elevations in two patients. An oral presentation of the results is scheduled for February 6, 2026, and the presentation will be available on uniQure's website following the event.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDLMPT6D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014013.SGD","LU2210150020.SGD","LU0889565916.HKD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4112","QURE","BK4139","LU0320765992.SGD","SG9999014039.USD","LU2210149790.SGD","LU0109394709.USD","BK4588","NDAQ","IE00BGHQF748.EUR","LU2095319765.USD"],"gpt_icon":0},{"id":"2608807834","title":"A Look At uniQure (QURE) Valuation After FDA Setback And Legal Investigations","url":"https://stock-news.laohu8.com/highlight/detail?id=2608807834","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608807834?lang=en_us&edition=fundamental","pubTime":"2026-02-04 01:16","pubTimestamp":1770138994,"startTime":"0","endTime":"0","summary":"uniQure (NasdaqGS:QURE) is back in focus after disclosing that the FDA views current AMT-130 gene therapy data as insufficient for a Biologics License Application, clouding timelines and drawing legal and analyst scrutiny.\nSee our latest analysis for uniQure.\nThe FDA setback has come after a volatile period, with a 56.83% 1 year total shareholder return contrasting with an 18.86% 3 month share price decline and a smaller 5.60% year to date share price gain. This suggests that momentum has...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-fda-setback-and-legal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-fda-setback-and-legal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QURE","LU0109394709.USD","LU0889565916.HKD","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2606100117","title":"uniQure Initiated at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2606100117","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606100117?lang=en_us&edition=fundamental","pubTime":"2026-01-28 23:05","pubTimestamp":1769612700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 10:05 ET (15:05 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","QURE","BK4139","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2606548719","title":"Barclays Initiates Coverage on uniQure N.V With Equal Weight Rating, $31 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2606548719","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606548719?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:54","pubTimestamp":1769604879,"startTime":"0","endTime":"0","summary":"uniQure N.V (QURE) has an average rating of Buy and mean price target of $50.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","BK4139","LU0889565916.HKD","QURE","LU0109394709.USD"],"gpt_icon":0},{"id":"2606753465","title":"uniQure initiated with an Equal Weight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2606753465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606753465?lang=en_us&edition=fundamental","pubTime":"2026-01-28 05:35","pubTimestamp":1769549744,"startTime":"0","endTime":"0","summary":"Barclays initiated coverage of uniQure (QURE) with an Equal Weight rating and $31 price target Barclays initiated coverage of 12 biotech stocks and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-initiated-with-an-equal-weight-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-initiated-with-an-equal-weight-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QURE","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2603642687","title":"uniQure NV Director Robert Gut Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603642687","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603642687?lang=en_us&edition=fundamental","pubTime":"2026-01-15 05:27","pubTimestamp":1768426024,"startTime":"0","endTime":"0","summary":"Robert Gut, Director, reported a disposal of common shares of uniQure NV. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL5xc3RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"uniQure NV Director Robert Gut Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","QURE","BK4139","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2603168448","title":"uniQure Showcases Gene Therapy Leadership and Pipeline Progress in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603168448","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603168448?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:15","pubTimestamp":1768310115,"startTime":"0","endTime":"0","summary":"uniQure NV has released a corporate presentation highlighting its advancements in gene therapy and providing updates on its clinical pipeline. The company reports robust progress, including upcoming data readouts for mesial temporal lobe epilepsy  and Fabry disease within the next three to six months. uniQure’s lead candidate, AMT-130, is positioned as a potential first disease-modifying therapy for Huntington’s disease. The presentation also notes ongoing engagement with the FDA regarding the pathway to Biologics License Application  submission, and outlines the company’s strong financial position with approximately $694.2 million in cash, cash equivalents, and investment securities as of September 30, 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL3g4zwJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139"],"gpt_icon":0},{"id":"2603452610","title":"uniQure NV Director Jack Kaye Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603452610","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603452610?lang=en_us&edition=fundamental","pubTime":"2026-01-13 05:22","pubTimestamp":1768252927,"startTime":"0","endTime":"0","summary":"Jack Kaye, Director at uniQure NV, has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3h41SY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"uniQure NV Director Jack Kaye Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2602505305","title":"uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2602505305","media":"Benzinga","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602505305?lang=en_us&edition=fundamental","pubTime":"2026-01-10 02:14","pubTimestamp":1767982440,"startTime":"0","endTime":"0","summary":"uniQure N.V. (NASDAQ:QURE) shares are popping on Friday after the company said the FDA will review the data package for AMT‑130, its gene therapy for Huntington's disease, with a Type A meeting now scheduled.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/09/Health-care--Lab.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/09/Health-care--Lab.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49820753/uniqure-stock-jumps-after-scheduling-fda-type-a-meeting-for-amt%e2%80%91130-approval-pathway","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49820753/uniqure-stock-jumps-after-scheduling-fda-type-a-meeting-for-amt%e2%80%91130-approval-pathway","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4084","BK4585","QURE","BK4219","BK4554","BK4139","LU0889565916.HKD","BK4581","BK4534","LU0320765992.SGD","LU0109394709.USD","AMT","BK4588"],"gpt_icon":0},{"id":"2602581376","title":"US-Listed Shares of Uniqure Rise 13% Premarket as FDA Review Talks Revive Hopes for Huntington's Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2602581376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602581376?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:08","pubTimestamp":1767964091,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0889565916.HKD","QURE","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2602375913","title":"BUZZ-UniQure rises as US FDA review talks revive hopes for Huntington's therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375913","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602375913?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:51","pubTimestamp":1767963066,"startTime":"0","endTime":"0","summary":"BUZZ-UniQure rises as US FDA review talks revive hopes for Huntington's therapy** U.S.-listed shares of Dutch firm UniQure UQ1.F, QURE.O rise 16% to $26.90 premarket** Co says it has scheduled Type A meeting with U.S. FDA to discuss data for potential marketing application for AMT-130** Co seeks accelerated approval for AMT-130, a gene therapy for Huntington's disease, which is a type of brain disorder with no approved treatments** In September, trial data showed AMT130 slowed disease progression by 75%, sending QURE shares soaring more than threefold** However, in November, health regulator said trial data may be inadequate to support marketing application, prompting shares to plunge** UniQure climbed 32% in 2025   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nL4N3YA0W0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","QURE","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2602736983","title":"uniQure announces Type A meeting scheduled with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2602736983","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602736983?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:13","pubTimestamp":1767960789,"startTime":"0","endTime":"0","summary":"uniQure (QURE) announced a Type A meeting with the U.S. Food and Drug Administration has been scheduled to discuss the Biologics License Applicatio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-announces-type-a-meeting-scheduled-with-fda-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-announces-type-a-meeting-scheduled-with-fda-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","QURE","BK4139","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2592924426","title":"Does uniQure (QURE) FDA Feedback on AMT-130 Reframe Its Risk, Funding and Strategy Profile?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592924426","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592924426?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:34","pubTimestamp":1766021682,"startTime":"0","endTime":"0","summary":"In early December 2025, uniQure reported that final FDA meeting minutes indicated Phase I/II data for its Huntington's gene therapy AMT-130 are currently unlikely to provide the primary evidence needed for a Biologics License Application, prompting the company to seek a follow-up meeting in early 2026.\nThis feedback raises questions about trial design, endpoint robustness, and the potential need for additional studies, sharpening focus on uniQure’s regulatory pathway and funding capacity for...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/does-uniqure-qure-fda-feedback-on-amt-130-reframe-its-risk-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/does-uniqure-qure-fda-feedback-on-amt-130-reframe-its-risk-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4219","AMT","BK4139","QURE","LU0109394709.USD","BK4585","BK4581","BK4588","LU0889565916.HKD","BK4554","BK4084","BK4534","LU0320765992.SGD"],"gpt_icon":0},{"id":"2592932207","title":"uniQure call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2592932207","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592932207?lang=en_us&edition=fundamental","pubTime":"2025-12-17 04:05","pubTimestamp":1765915512,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in uniQure (QURE) with 4,979 calls trading, 1.1x expected, and implied vol increasing almost 4 points to 84.35%. Jan-2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0889565916.HKD","QURE","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2592939206","title":"What's Going On With uniQure Stock On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592939206","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592939206?lang=en_us&edition=fundamental","pubTime":"2025-12-17 01:17","pubTimestamp":1765905420,"startTime":"0","endTime":"0","summary":"uniQure shares slid nearly 31% in a month as the FDA raised concerns over whether AMT-130 Phase 1/2 data can support approval.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/16/Indecision-In-The-Stock-Or-Crypto-Market.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/16/Indecision-In-The-Stock-Or-Crypto-Market.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/biotech/25/12/49428299/whats-going-on-with-uniqure-stock-on-tuesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/25/12/49428299/whats-going-on-with-uniqure-stock-on-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["QURE","LU0109394709.USD","BK4139","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2589831064","title":"uniQure Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589831064","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589831064?lang=en_us&edition=fundamental","pubTime":"2025-12-05 02:52","pubTimestamp":1764874320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 13:52 ET (18:52 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","QURE","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":-0.1112},{"period":"1month","weight":-0.0241},{"period":"3month","weight":-0.1796},{"period":"6month","weight":0.5659},{"period":"1year","weight":0.8116},{"period":"ytd","weight":0.0326}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.009035},{"month":2,"riseRate":0.583333,"avgChangeRate":0.066179},{"month":3,"riseRate":0.25,"avgChangeRate":-0.054124},{"month":4,"riseRate":0.416667,"avgChangeRate":0.018299},{"month":5,"riseRate":0.666667,"avgChangeRate":0.042965},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.009437},{"month":7,"riseRate":0.25,"avgChangeRate":0.033059},{"month":8,"riseRate":0.5,"avgChangeRate":0.005984},{"month":9,"riseRate":0.25,"avgChangeRate":0.122705},{"month":10,"riseRate":0.5,"avgChangeRate":0.060394},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure NV","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"uniQure NV,QURE,uniQure NV股票,uniQure NV股票老虎,uniQure NV股票老虎国际,uniQure NV行情,uniQure NV股票行情,uniQure NV股价,uniQure NV股市,uniQure NV股票价格,uniQure NV股票交易,uniQure NV股票购买,uniQure NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}